Medicine
Pyrukynd 5 mg tablet
Pyrukynd 5 mg tablet is a prescription medicine containing Mitapivat for oral use, marketed by Agios Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C…
Key facts
- Active ingredient (INN)
- Mitapivat
- Brand
- Pyrukynd
- Strength
- 5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 4 blister pack, 1 blister pack
- Marketing authorisation holder
- Agios Pharmaceuticals
- Manufacturer
- Agios Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Store the blister wallets in the original carton until use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B06AX04 Mitapivat
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 February 2022
- Identifiers
- RxCUI 2594473, 2594479, 2594496 +7DailyMed set ID 4ccee896-e313-4c6c-9674-b4746ada0a90NDC 71334-205, 71334-220Application NDA216196
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 blister pack in 1 carton / 14 tablet, film coated in 1 blister pack | 71334-205-05 | Agios Pharmaceuticals | 18 February 2022 |
| 1 blister pack in 1 carton / 7 tablet, film coated in 1 blister pack | 71334-220-11 | Agios Pharmaceuticals | 18 February 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Mitapivat
Clinical summary
Mitapivat is a pyruvate kinase activator indicated for the treatment of anemia in adults with alpha- or beta-thalassemia. It is available as tablets and kits for oral use. MedsAcross supplies Mitapivat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MitapivatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- AQVESME prescribing information (Agios Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Pyrukynd: European public assessment report (EPAR) · European Medicines Agency
Need Pyrukynd 5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.